(Boursier.com) — Eligo Bioscience, company? pioneer of genetic editing, announces a fundraising of 30 million dollars (27.5 million euros), notably in order to generate a proof of concept at patients with its first drug candidate, EB005, treating acne? moderate? has? severe. This new generation gene therapy is based on CRISPR technology developed by Eligo which makes it possible to correct defective genes in the microbiome. Is the round table completed? by Sanofi Ventures, supports? from Bpifrance to? through the InnoBio 2 fund, and historic investors from Eligo Bioscience, Khosla Ventures and Seventure Partners.
Laia Crespo, partner at Sanofi Ventures and Benoit Barteau, investment director at Bpifrance, join the Board of Directors of Eligo Bioscience.
©2023 Boursier.com